Manipal Hospitals to Acquire Sahyadri for ₹6,400 Cr in Major Healthcare Deal

New Delhi — In a major development in India’s private healthcare landscape, Manipal Hospitals has sought approval from the Competition Commission of India (CCI) to acquire Sahyadri Hospitals, a leading Western India-based hospital chain, for a reported ₹6,400 crore.

This strategic move is expected to bolster Manipal’s footprint in Maharashtra and consolidate its position as one of the top three hospital networks in the country by bed capacity and revenue.

🏥 Sahyadri’s Presence:

Sahyadri Hospitals operates nine multi-speciality hospitals across cities like Pune, Nashik, and Karad, with a total bed strength of over 900 beds. The chain is known for its strong clinical specialties in oncology, neurology, cardiology, and organ transplants.

💼 Strategic Push by Manipal:

Manipal Hospitals, backed by global investment firm TPG Capital, has been actively expanding. The group previously acquired Columbia Asia and Vikram Hospital, building one of India’s largest integrated health networks.

This latest deal signals continued consolidation in India’s private healthcare market, driven by the rising demand for quality tertiary care, operational synergies, and access to underserved regional hubs.

🔍 What Comes Next:

The acquisition plan now awaits CCI’s approval, which is a mandatory regulatory step to ensure compliance with India’s antitrust laws. If cleared, the integration is likely to enhance patient access to Manipal’s standardised protocols, advanced medical tech, and streamlined care delivery across Western India.

Related Posts

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India